Patents by Inventor David R Witty

David R Witty has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Quinoline derivatives and their use as 5-HTligands
    Patent number: 8236947
    Abstract: Disclosed are quinoline compounds having affinity for the 5-HT6 receptor and having the formula: where R1, R2, R3, R4, R5, n, m, p and A are defined herein, and salts thereof, compositions containing these compounds and salts and processes for making and using the same.
    Type: Grant
    Filed: June 3, 2011
    Date of Patent: August 7, 2012
    Assignee: Glaxo Group Limited
    Inventors: Mahmood Ahmed, Christopher Norbert Johnson, Martin C Jones, Gregor James MacDonald, Stephen Frederick Moss, Mervyn Thompson, Charles Edward Wade, David R Witty
  • Quinoline derivatives and their use as 5-HT6 ligands
    Patent number: 7977337
    Abstract: Disclosed are quinoline compounds having affinity for the 5-HT6 receptor and having the formula: where R1, R2, R3, R4, R5, n, m, p and A are defined herein, and salts thereof, compositions containing these compounds and salts and processes for making and using the same.
    Type: Grant
    Filed: July 30, 2010
    Date of Patent: July 12, 2011
    Assignee: Glaxo Group Limited
    Inventors: Mahmood Ahmed, Christopher Norbert Johnson, Martin C Jones, Gregor James MacDonald, Stephen Frederick Moss, Mervyn Thompson, Charles Edward Wade, David R Witty
  • Quinoline derivatives and their use as 5-HTligands
    Patent number: 7799774
    Abstract: Disclosed are quinoline compounds having affinity for the 5-HT6 receptor and having the formula: where R1, R2, R3, R4, R5, n, m, p and A are defined herein, and salts thereof, compositions containing these compounds and salts and processes for making and using the same.
    Type: Grant
    Filed: August 14, 2009
    Date of Patent: September 21, 2010
    Assignee: Glaxo Group Limited
    Inventors: Mahmood Ahmed, Christopher Norbert Johnson, Martin C Jones, Gregor James MacDonald, Stephen Frederick Moss, Mervyn Thompson, Charles Edward Wade, David R Witty
  • Quinoline derivatives and their use as 5-HT6 ligands
    Patent number: 7601837
    Abstract: The present invention relates to novel quinoline compounds having pharmacological activity, to processes for their preparation, to compositions containing them and to their use in the treatment of CNS and other disorders.
    Type: Grant
    Filed: September 5, 2008
    Date of Patent: October 13, 2009
    Assignee: Glaxo Group Limited
    Inventors: Mahmood Ahmed, Christopher Norbert Johnson, Gregor James MacDonald, Stephen Frederick Moss, Mervyn Thompson, David R Witty
  • 5-Sulfonyl-1-Piperidinyl Substituted Indole Derivatives as 5-Ht6 Receptor Antagonists for the Treatment of Cns Disorders
    Publication number: 20080318933
    Abstract: The present invention relates to novel indole derivatives such as compounds of the formula (I): which possess antagonist potency at the 5-HT6 receptor and the use of such compounds or pharmaceutically acceptable salts or solvates thereof in the treatment of Alzheimer's disease and other CNS disorders.
    Type: Application
    Filed: October 5, 2005
    Publication date: December 25, 2008
    Inventors: Mahmood Ahmed, Christopher Norbert Johnson, Neil Derek Miller, Peter Henry Milner, Dean Andrew Rivers, David R Witty
  • Quinoline derivatives and their use as 5-ht6 ligands
    Patent number: 7452888
    Abstract: Disclosed are novel quinoline compounds of formula (I), processes for their preparation, compositions containing them and their use in the treatment of CNS disorders.
    Type: Grant
    Filed: March 25, 2003
    Date of Patent: November 18, 2008
    Assignee: Glaxo Group Limited
    Inventors: Mahmood Ahmed, Christopher Norbert Johnson, Martin C Jones, Gregor James Macdonald, Stephen Frederick Moss, Mervyn Thompson, Charles Edward Wade, David R Witty
  • Quinoline compounds and pharmeceutical compositions containing them
    Patent number: 7439244
    Abstract: Disclosed are quinoline compounds of formula (I) having pharmacological activity, processes for their preparation, compositions containing them, and methods for the treatment of CNS and other disorders.
    Type: Grant
    Filed: September 9, 2004
    Date of Patent: October 21, 2008
    Assignee: Glaxo Group Limited
    Inventors: Christopher Norbert Johnson, David R Witty
  • Piperazinyl-quinoline derivatives useful for the treatment of CNS disorders
    Patent number: 7439243
    Abstract: Disclosed are quinoline compounds of formula (I) having pharmacological activity, processes for their preparation, compositions containing them, and methods for the treatment of CNS and other disorders.
    Type: Grant
    Filed: September 23, 2004
    Date of Patent: October 21, 2008
    Assignee: Glaxo Group Limited
    Inventors: Christopher Norbert Johnson, Stephen Frederick Moss, David R Witty
  • 3-arylsulfonyl-7-piperzinyl-indoles-benzofurans and -benzothiophenes with 5-ht6 receptor affinity for treating cns disorders
    Publication number: 20040242589
    Abstract: The invention relates to novel compounds of formula (I) having affinity for the 5-HT6 receptor preparation, to compositions containing them and their use in the treatment of various disorders, including CNS disoders.
    Type: Application
    Filed: February 6, 2004
    Publication date: December 2, 2004
    Inventors: Steven Mark Bromidge, Christopher Norbert Johnson, Gregor James MacDonald, Mervyn Thompson, David R Witty
  • .beta.-thiopropionyl-aminoacid derivatives and their use as .beta.-lactamase inhibitors
    Patent number: 6048852
    Abstract: A method of treatment of bacterial infections in humans or animals which comprises administering, in combination with a .beta.-lactam antibiotic, a therapeutically effective amount of an amino acid derivative of Formula (I) or a pharmaceutically acceptable salt, solvate or in vivo hydrolysable ester thereof, ##STR1## wherein: R is hydrogen, a salt forming cation or an in vivo hydrolysable ester-forming group; R.sub.1 is hydrogen, (C.sub.1-6)alkyl optionally substituted by up to three halogen atoms or by a mercapto, (C.sub.1-6)alkoxy, hydroxy, amino, nitro, carboxy, (C.sub.1-6)alkylcarbonyloxy, (C.sub.1-6)alkoxycarbonyl, formyl or (C.sub.1-6)alkylcarbonyl group, (C.sub.3-7)cycloalkyl, (C.sub.3-7)cycloalkyl(C.sub.2-6)alkyl, (C.sub.2-6)alkenyl, (C.sub.2-6)alkynyl, aryl, aryl(C.sub.1-6)alkyl, heterocyclyl or heterocyclyl(C.sub.1-6)alkyl; R.sub.2 is hydrogen, (C.sub.1-6)alkyl or aryl(C.sub.1-6)alkyl; R.sub.3 is hydrogen, (C.sub.1-6)alkyl optionally substituted by up to three halogen atoms, (C.sub.
    Type: Grant
    Filed: January 13, 1999
    Date of Patent: April 11, 2000
    Assignee: SmithKline Beecham p.l.c.
    Inventors: John Hargreaves Bateson, David R Witty, Brian Charles Gasson, Desmond John Best, David John Payne